A single subcutaneous injection provides 5 days of CINV protection1

SUSTOL was designed to offer lasting CINV prevention1,2

  • SUSTOL is supplied as a refrigerated kit with a single-dose, sterile, pre-filled glass syringe that contains 10 mg of granisetron/0.4 mL
  • SUSTOL should be administered at least 30 minutes before chemotherapy
  • Store SUSTOL in the refrigerator at 2°C to 8°C (36°F to 46°F). DO NOT FREEZE
  • SUSTOL may be left out at room temperature overnight, and for up to 7 days, before it must be discarded. SUSTOL may be re-refrigerated if not used within the 7-day period
  • Protect from light
Items included in the SUSTOL kit
View IFU
Please review all Instructions for Use (IFU) included
with the medication prior to administration.

One convenient kit allows for administration with three basic steps

SUSTOL administration step 1

READY SUSTOL by removing from refrigeration and unpacking kit at least 60 minutes prior to administration to allow SUSTOL and the warming pouches to reach room temperature.2

SUSTOL administration step 2

WARM SUSTOL to body temperature by wrapping assembled syringe in activated warming pouch for 5-6 minutes. Do NOT remove blue needle cover.2

SUSTOL administration step 3

INJECT SUSTOL subcutaneously in upper arm or abdomen using a firm and steady push. Pressing plunger harder will not expel SUSTOL faster.2

To help facilitate administration, SUSTOL must be at body temperature immediately prior to injection2
See how to properly administer SUSTOL
CINV=chemotherapy-induced nausea and vomiting.

INDICATION

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

IMPORTANT SAFETY INFORMATION

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Report side effects to Heron at 1-844-437-6611.

Please see full Prescribing Information, including Medication Guide.

Reference:
  1. SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.
  2. SUSTOL [instructions for use]. Heron Therapeutics, Inc., 2017.
  3. Schnadig et al. Future Oncol. 2016.
  4. Zhou et al. Ther Clin Risk Manag. 2015.




INDICATION

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

IMPORTANT SAFETY INFORMATION

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Report side effects to Heron at 1-844-437-6611.

Please see full Prescribing Information, including Medication Guide.